Checkit Still Trades Below the Sale-Process Math

Summary: Checkit closed at 25.50p on 8 May 2026, leaving the company worth about GBP27.5 million at the equity level. After backing out the GBP3.0 million cash balance disclosed in the latest annual results, the enterprise value is roughly GBP24.5 million, or about 1.7x annual recurring revenue. That is not a distressed multiple. It is still a public-orphan multiple for a business that has already turned adjusted EBITDA positive, launched a formal sale process, approached more than 25 counterparties, and received six unsolicited preliminary expressions of interest. The disagreement is between a live M&A process and a valuation that still looks half public, half stranded.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	Checkit still trades below sale-process math [1][2][3][10]	Europe / UK small-cap software / formal sale process	The stock still sits at only about 1.7x EV / ARR even after the March-April rerating, while the board has already launched a formal sale process, documented outside interest, and reported adjusted EBITDA profitability.	LSE quote page as at 9 May 2026 08:14:27 Singapore time; final results on 21 April 2026; sale-process announcement on 26 March 2026	Immediate to medium term through any Rule 8 escalation, bidder emergence, or process termination	High because the downside is visible in the pre-process trading range, while a strategic bid can still reset the whole multiple	There may be no firm bid, and the stock can slide back into the high teens if the process ends without a transaction
2	Ruger's Beretta tender premium looks cleaner than it is [4][5]	U.S. partial tender / governance event	A headline $44.80 tender price looks attractive against a stock around $39, and the governance pact is fresh	Fresh quote and 8-K filed last week	Conditional, but visible	Moderate	Beretta only needs to buy up to 15.05% of the company, so the blended payoff is much messier than the headline premium suggests
3	Taiyo's above-bid trading is real, but the clock is too long [6][7]	Japan above-bid TOB / privatization	Taiyo still trades around JPY4,900 against a JPY4,750 tender price, which means the market is still pricing bump optionality	Official privatization documents from 31 March 2026 and quote pages updated through 8 May 2026	Slow. Commencement is expected around early October 2026	Moderate	The market may be right about bump optionality, but the time cost is too high for a clean daily note
4	Vedanta's post-demerger stub has already repriced [8][9]	Broader Asia demerger / residual stub	The residual stock reset toward the broker-indicated INR300-325 zone once the 1 May 2026 record date passed	Record-date and post-demerger coverage printed in the last two weeks	Mostly spent	Low	The entitlement window is gone, and the residual line already sits close to the published broker range

Selected opportunity: Checkit still trades below sale-process math.

Why this one now: It offers the best mix of still-open asymmetry and fresh process evidence. The price has moved enough to confirm that the market finally noticed the asset, but not enough to price a credible software-sale outcome.

What should surprise the reader: The surprise is not that Checkit found buyers. The surprise is that even after the rerating, the public market is still valuing an active sale-process software asset at a multiple that looks closer to an unwanted AIM listing than to a strategic workflow platform with recurring revenue.

Geographic Search Audit

U.S. candidate screened: Sturm, Ruger. The headline premium is real, but the partial tender structure leaves too much residual-stub uncertainty for a clean payoff map. [4][5]
Japan candidate screened: Taiyo Holdings. The above-bid pricing is interesting, but the tender is expected to start only around early October 2026, which makes the time cost too punitive for this format. [6][7]
Broader Asia candidate screened: Vedanta residual stub. The demerger record-date dislocation was real, but the straightforward edge has already been repriced into the post-split line. [8][9]
Europe / UK candidate screened: Checkit, selected. The stock still prices the company like a public orphan even though the sale process is live and the business has already crossed into adjusted EBITDA profitability. [1][2][3][10]
If any lane was rejected, why: U.S. was rejected on payoff messiness, Japan on timeline drag, and broader Asia because the clean residual-stub edge is largely gone.

Why This Is the Best Opportunity Right Now

Checkit has already crossed the threshold that usually kills the pure value-trap argument. The company reported GBP14.7 million of revenue for the year ended 31 January 2026, GBP14.3 million of ARR, and GBP0.3 million of adjusted EBITDA, versus a GBP2.3 million loss a year earlier. Cash ended the year at GBP3.0 million. [1][10]

Then the board did something public-market holders rarely get in time. On 26 March 2026, it stopped pretending the market would eventually solve the valuation problem by itself. Checkit announced a formal sale process, said it had already approached more than 25 potential counterparties, and disclosed that it had received six unsolicited preliminary expressions of interest. [2]

The stock noticed. It moved from the mid-teens to the mid-twenties. But the rerating still looks incomplete.

At 25.50p, Checkit's equity value is about GBP27.5 million. Subtract the GBP3.0 million year-end cash balance and the enterprise value is roughly GBP24.5 million. Against GBP14.3 million of ARR, the market is still paying only about 1.7x EV / ARR. [1][3][10]

That is the disagreement. The market is no longer pricing Checkit for extinction. It still is not pricing it like a live sale-process software asset.

What Should Surprise the Reader

The public-market story says the straightforward rerating has already happened because the stock has doubled off the lows and now sits only about 5.6% below its 52-week high of 27.00p. [3][10]

That framing misses the more important arithmetic. A company can rerate sharply and still remain cheap if the starting point was wrong enough. Checkit today still looks closer to a neglected AIM multiple than to even a modest strategic-software takeout multiple. The stock has moved. The valuation regime has not moved as far.

The Setup

Checkit sells operational workflow software used to monitor people, sites, and assets across field-heavy environments such as healthcare, food, and facilities operations. The business is no longer in the "interesting product, no proof" bucket.

The final results announcement on 21 April 2026 made that clear. ARR was GBP14.3 million. Revenue was GBP14.7 million. Adjusted EBITDA turned positive at GBP0.3 million. The company also said underlying ARR growth was 5% after excluding a single large U.S. customer reduction related to unused services. [1]

The same announcement repeated that the formal sale process announced on 26 March 2026 remains ongoing and explicitly stated the board's view that the current public-market valuation does not fully reflect the company's quality, scalability, and long-term potential. [1][10]

That matters because the formal sale process was not launched in a vacuum. The board had already retained advisers, canvassed the market, and turned private interest into a structured process. [2]

The Market Price

Item	Level	Why It Matters	Source
Previous close price	25.50p	Current reference line	London Stock Exchange company page, as at 9 May 2026 08:14:27 Singapore time [3]
Open price	25.00p	Confirms the stock is holding the sale-process rerating band	LSE company page [3]
52-week range	12.35p to 27.00p	The stock is no longer washed out. This is a valuation and process thesis, not a pure technical rebound	LSE company page [3]
Shares in issue	108,008,562	Needed for current equity-value math	Formal sale process announcement [2]
Equity value	about GBP27.5 million	Current market value of the public equity	Derived from [2][3]
Year-end cash	GBP3.0 million	Cash support under the equity and a key EV adjustment	Final results [1]
Enterprise value	about GBP24.5 million	The number strategic buyers care about more than market cap	Derived from [1][2][3]
ARR	GBP14.3 million	Current recurring-revenue anchor	Final results [1]
EV / ARR	about 1.7x	Core mispricing metric	Derived from [1][2][3]
Revenue	GBP14.7 million	Confirms this is a real commercial platform, not a pre-revenue story	Final results [1]
Adjusted EBITDA	GBP0.3 million	The company already crossed into adjusted profitability	Final results [1]
Formal sale process outreach	More than 25 counterparties approached; six unsolicited preliminary expressions of interest received	Shows the board already created real strategic tension, not just a vague review	Formal sale process announcement [2]

The simplest way to phrase the gap is this: a public market that now knows the asset is in play is still pricing it at only about 1.7x recurring revenue.

The Positioning

I do not have sufficient reliable live short-interest, borrow-cost, or options-skew data to quantify hedge-fund positioning accurately. That missing data should be stated, not papered over.

What can be said with evidence is narrower. Checkit is in an offer period, and the London Stock Exchange news feed still showed fresh Rule 8.5 disclosure traffic into 6 May 2026. [11] That is not proof of crowding. It is proof that event-driven participants are still watching the file.

The more important positioning point is structural. Checkit remains a small AIM name with limited natural sponsorship. A stock can be obviously in play and still be underowned because many institutions will not spend time on a company this small unless a transaction becomes firmer. That is exactly the sort of gap a formal process can close quickly.

One more thing is worth stating plainly. The chart is not doing the work here. The stock is already near the top of its 52-week range. [3][10] If the thesis cannot survive without a momentum breakout, it is not good enough. This one survives because the valuation still looks low relative to the process and the recurring-revenue base.

The Catalyst

The catalyst is the process itself.

That sounds vague, but in U.K. offer situations there is a meaningful difference between "strategic review" language and a declared formal sale process under the Takeover Code. Checkit has already crossed into the second category. [2]

The market does not need a heroic operating surprise from here. It needs one of three things:

a firm bid,
a clearer narrowing of bidders inside the offer process, or
a fresh operating update that makes the public-orphan multiple harder to defend even without a sale.

The closing mechanism is observable even if it is not date-stamped to a single earnings print. Every new Rule 8 filing keeps the process alive. Any firm offer or termination announcement would compress the uncertainty immediately. [11]

The Gap

What the market appears to price: A micro-cap U.K. software stock that might attract interest but still deserves a near-public-market recurring-revenue multiple because a deal is uncertain.

What may be wrong: Once a board has already canvassed more than 25 counterparties, disclosed six preliminary expressions of interest, and reported adjusted EBITDA profitability, the default multiple should no longer look like an abandoned standalone case. [1][2]

Why the market may be right: Small-cap software sale processes do fail. Buyers can balk at scale, customer concentration, procurement-heavy sales cycles, or the simple friction of integrating a sub-GBP15 million revenue asset. The board itself says there is no certainty any offer will be made. [10]

Why the market may be wrong: Even after the rerating, the stock still prices the enterprise at only about 1.7x ARR with cash on the balance sheet and a live process. That still looks too low for a business that has already reached an operational inflection point and is now being actively marketed.

The Payoff Map

The cleanest expression is long common stock.

Not because the stock is technically oversold. It is not.

The long works because the public market still appears to be applying the wrong multiple regime to an asset that is already in motion. The upside does not require a heroic software bubble. It requires either a credible strategic bid or a public-market re-rating toward a more sensible recurring-revenue multiple once the sale process keeps proving that the asset is real.

I do not prefer options here. I did not verify a live listed options market with acceptable liquidity, and small-cap U.K. options liquidity is often poor even when contracts exist. A common-stock expression matches the thesis better than a guessed options structure.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	20%	44.0p	+72.5%	2 to 6 months	Formal sale process produces a credible strategic bid at a low-3x EV / ARR area, or competitive tension forces the market close to that outcome	Medium
Base Case	50%	34.0p	+33.3%	2 to 6 months	Process remains alive, the market moves from a 1.7x EV / ARR anchor toward a mid-2x multiple, and the company maintains profitability and cash discipline	Medium
Bottom Case	30%	18.0p	-29.4%	1 to 4 months	Formal sale process ends without a transaction, operating momentum softens, and the stock falls back toward the pre-process valuation band	Medium
Invalidation / Stop Condition	n/a	Below 18.0p on adverse process or operating news	Thesis broken	Immediate	Formal sale process is terminated without a compensating strategic alternative, or fresh results show the inflection was weaker than advertised	High

Probability-weighted expected value: 31.4p, or about 23.1% above the current 25.50p reference price.

Current market price / level: 25.50p previous close on the London Stock Exchange quote page, as at 9 May 2026 08:14:27 Singapore time. [3]

Timestamp: 11 May 2026, Singapore time.

Primary instrument: CKT common stock.

Alternative expressions considered: Waiting for a firmer bid, avoiding the trade until a new trading update, or using options. Waiting reduces process risk but gives up the cheapest part of the re-rating if a bidder emerges. Options were rejected because I did not verify a liquid live chain.

Confidence: Medium.

What Could Go Wrong

The strongest simple risk is that the board has created attention, not a deal.

Formal sale processes can fail. Small buyers can struggle to finance acquisitions cleanly. Larger buyers can decide that a niche workflow asset is easier to compete with than to buy. If that happens, the stock can revisit the high teens quickly because many of the new holders are there for the process, not for a five-year standalone compounding story.

There is also a quality-of-asset risk. ARR growth was helped by excluding a single large U.S. customer reduction to get to the underlying growth frame. [1] That adjustment is reasonable to examine, but it also tells you the business is not frictionless.

Finally, liquidity is a real risk. This is an AIM stock. Price gaps can be larger than the underlying change in expected value.

What Would Prove This Wrong

This thesis fails if any of the following happens:

the formal sale process ends without a transaction and without a stronger standalone re-rating case,
a new operating update shows cash erosion or a fresh deterioration in recurring revenue quality,
the company falls materially below 18.0p because the board has lost strategic leverage, not because the broader market is simply noisy, or
new disclosure makes it clear that buyers were interested only at prices not meaningfully above where the stock already traded.

If those things happen, the market is not missing the asset. It is correctly pricing its limits.

Risk Audit

Strongest counterargument: The stock already doubled off the lows. The easy mispricing is over. The remaining spread is just a board hoping a software process becomes a deal.

Most fragile assumption: That at least one real buyer can pay materially above the current line for a business of this scale.

What the market may already know: Investors may already understand that the process is real and still be unwilling to pay more because failed micro-cap software auctions are common enough to deserve a discount.

What could make the trade lose money even if the thesis is directionally right: The public market could eventually re-rate the asset correctly, but only after a failed or delayed process first forces the stock lower.

Liquidity / execution risks: This is a small AIM stock with limited depth. Entry and exit discipline matters more than in a large-cap name.

Leverage risks: I did not verify a usable listed options market. Levered expressions would add complexity without fresh evidence that the payoff improves.

Information reliability risks: The core facts are public and recent, but precise bidder quality, process stage, and buyer willingness to pay remain opaque until a firmer announcement arrives.

Invalidation trigger: Termination of the formal sale process without a compensating strategic alternative, or a fundamental deterioration that makes the current 1.7x EV / ARR multiple fair rather than too low.

Publish / revise / reject recommendation: Publish.

Bottom Line

Checkit no longer looks like a pure story stock. The company has recurring revenue, adjusted EBITDA profitability, cash on the balance sheet, and a live formal sale process backed by disclosed outside interest. At 25.50p, the market has admitted that something is happening. It still has not fully priced what that something could be worth.

Research Quality Scorecard

The full scorecard is kept in the companion meta file.

Sources

Best trade: Long common stock.